Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup

Recurrent disease

on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or=12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is>12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).

Original languageEnglish
Article numbermdw663
Pages (from-to)727-732
Number of pages6
JournalAnnals of Oncology
Volume28
Issue number4
DOIs
Publication statusPublished - 2017 Apr 1
Externally publishedYes

Fingerprint

Platinum
Ovarian Neoplasms
Neoplasms
Clinical Trials
Therapeutics
Survival
Tokyo
Biological Factors
Histology
Japan
Quality of Life
Mutation
Pharmaceutical Preparations

Keywords

  • Clinical trials
  • Ovarian cancer
  • Recurrent disease

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference (2017). Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease. Annals of Oncology, 28(4), 727-732. [mdw663]. https://doi.org/10.1093/annonc/mdw663

Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup : Recurrent disease. / on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference.

In: Annals of Oncology, Vol. 28, No. 4, mdw663, 01.04.2017, p. 727-732.

Research output: Contribution to journalReview article

on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference 2017, 'Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease', Annals of Oncology, vol. 28, no. 4, mdw663, pp. 727-732. https://doi.org/10.1093/annonc/mdw663
on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease. Annals of Oncology. 2017 Apr 1;28(4):727-732. mdw663. https://doi.org/10.1093/annonc/mdw663
on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference. / Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup : Recurrent disease. In: Annals of Oncology. 2017 ; Vol. 28, No. 4. pp. 727-732.
@article{1726341c3dfa40d3b51e4080c715a4b7,
title = "Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease",
abstract = "This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or=12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is>12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).",
keywords = "Clinical trials, Ovarian cancer, Recurrent disease",
author = "{on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference} and Wilson, {M. K.} and E. Pujade-Lauraine and Daisuke Aoki and Mirza, {M. R.} and D. Lorusso and Oza, {A. M.} and {du Bois}, A. and I. Vergote and A. Reuss and M. Bacon and M. Friedlander and D. Gallardo-Rincon and F. Joly and Chang, {S. J.} and Ferrero, {A. M.} and Edmondson, {R. J.} and P. Wimberger and J. Maenpaa and D. Gaffney and R. Zang and A. Okamoto and G. Stuart and K. Ochiai",
year = "2017",
month = "4",
day = "1",
doi = "10.1093/annonc/mdw663",
language = "English",
volume = "28",
pages = "727--732",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup

T2 - Recurrent disease

AU - on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference

AU - Wilson, M. K.

AU - Pujade-Lauraine, E.

AU - Aoki, Daisuke

AU - Mirza, M. R.

AU - Lorusso, D.

AU - Oza, A. M.

AU - du Bois, A.

AU - Vergote, I.

AU - Reuss, A.

AU - Bacon, M.

AU - Friedlander, M.

AU - Gallardo-Rincon, D.

AU - Joly, F.

AU - Chang, S. J.

AU - Ferrero, A. M.

AU - Edmondson, R. J.

AU - Wimberger, P.

AU - Maenpaa, J.

AU - Gaffney, D.

AU - Zang, R.

AU - Okamoto, A.

AU - Stuart, G.

AU - Ochiai, K.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or=12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is>12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).

AB - This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or=12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is>12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).

KW - Clinical trials

KW - Ovarian cancer

KW - Recurrent disease

UR - http://www.scopus.com/inward/record.url?scp=85018501356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018501356&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw663

DO - 10.1093/annonc/mdw663

M3 - Review article

VL - 28

SP - 727

EP - 732

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

M1 - mdw663

ER -